key: cord-0921703-ueicesub
authors: Woodruff, Trent M.; Shukla, Arun K.
title: The complement C5a-C5aR1 GPCR axis in COVID-19 therapeutics
date: 2020-09-23
journal: Trends Immunol
DOI: 10.1016/j.it.2020.09.008
sha: 3ee9c560318145bea7bec228f1a7ac317eecb2bf
doc_id: 921703
cord_uid: ueicesub

The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.

of lung inflammation in COVID-19 could lead to targeted therapeutic approaches to reduce morbidity and mortality.

In a recent study in Nature, Carvelli and colleagues [1] examined immune alterations in healthy individuals and COVID-19 patients presenting with increasing disease severity -from paucisymptomatic individuals to those with pneumonia or ARDS. Plasma pro-inflammatory mediators including IL-6, CCL2, CCL4, and CXCL9 were positively associated with COVID-19 severity (Figure 1a ), as were increases in circulating neutrophils, supporting findings from prior reports [2] .

As an acute phase reactant that plays a key role in severe infections including pneumonia and sepsis, the complement cascade has been proposed as a possible driver of lung inflammation and the cytokine storm in COVID-19 [3, 4] . Indeed, SARS-CoV-2 proteins have been shown to activate distinct complement pathways [3, 5] . Complement is a key innate immune pathway that rapidly responds to pathogens and cellular injury and amplifies a range of innate and adaptive immune processes. One of the key drivers of complement-mediated inflammation, is the C5 cleavage product, C5a, which acts through two different seven transmembrane receptors, namely C5aR1 and C5aR2 [6] . The former is a member of the large superfamily of plasma membrane receptors, known as G proteincoupled receptors (GPCRs), which are involved in nearly every physiological process in mammals, including immune responses.

In line with increased plasma cytokine concentrations, Carvelli and co-workers reported that plasma C5a was elevated in COVID-19 patients, and correlated with disease severity, with median C5a concentrations in ARDS patients reaching >250% those of healthy controls (Figure 1a ) [1] . C5aR1 is highly expressed on myeloid cells in the healthy state, and indeed, no major alteration in neutrophil or monocyte receptor expression was observed in COVID-19 subjects. However, human monocytes co-stimulated with C5a and a toll-like receptor (TLR) pathway activator R848, drove the in vitro production of some of the same cytokines as those observed from COVID-19 patients ( [1] , thus supporting a role for C5a in chemoattracting these C5aR1-expressing cells into the injured lung [7] . Indeed, immunohistochemistry staining and single-cell RNAseq transcriptomic data supported high expression of C5aR1 across myeloid cells and pulmonary macrophages in COVID-19 lungs [1] .

There are currently multiple therapeutic candidates that target complement proteins at various stages of clinical development, with many of these drugs now undergoing clinical trials for COVID-19 disease. These approaches include blocking central complement factors C3 and C5, and their downstream activation cleavage products, complement pathway inhibitors (e.g. MASP-2 lectin pathway inhibitors), as well as specific complement effector molecules [3] . In the study by Carvelli and colleagues [1] , a targeted approach to C5aR1 was chosen to limit potentially immunocompromising consequences of blocking broader complement effector pathways, which might increase infection risk. Specifically, a fully human Fc-silent monoclonal antibody (mAb), avdoralimab (IPH5401), selectively blocked the C5a-C5aR1 interaction and its downstream signaling in human myeloid cells (Figure 1d ). This was confirmed by avdoralimab-mediated in vitro inhibition of C5a-mediated neutrophil chemotaxis and upregulation of adhesion molecule CD11b in neutrophils, suggesting that avdoralimab might be useful in preventing neutrophil recruitment in COVID-19 diseased lungs. As avdoralimab is specific to human C5aR1, its in vivo activity was tested in human C5aR1 knock-in (HuC5aR1) C57BL/6J mice (Figure 1e ): intra-nasal instillation of human C5a

induced key markers of acute lung inflammation [1] , consistent with those observed in samples from COVID-19 patients, namely, neutrophil and monocyte infiltration, vascular leakage, hemorrhage, and alveolar wall thickening [8] . These findings support the concept that C5a may constitute a key molecule that contributes to lung pathology in COVID-19 patients. Notably, avdoralimab treatment prior to C5a administration in this study led to marked reductions in leukocyte infiltration to the lung, attenuated lung edema, and reduced features of lung pathology relative to isotype-antibody control-treated animals, confirming a key role for myeloid cell-expressing C5aR1 in this mouse model (Figure 1e ) [1] . Moreover, avdoralimab also blocked C5a-mediated cytokine release from J o u r n a l P r e -p r o o f Journal Pre-proof blood monocytes isolated from COVID-19 patients (IL-6, TNF-α, CCL2) (Figure 1f ) [1] . Overall, the study by Carvelli et al. [1] provides promising evidence that blockade of a single, yet major GPCR in acute myeloid cell-mediated lung inflammation, might ameliorate the severity and mortality associated with COVID-19 ARDS. Evidently, this will require rigorous testing.

An open question remains as to whether other complement effectors such as C3a and the terminal membrane attack complex (C5b-9), contribute to COVID-19 disease. Furthermore, blocking C5aR1 with compounds such as avdoralimab, leaves open the possibility that enhanced C5a activity occurs at its other receptor ligand C5aR2, which may have an impact on COVID-19 disease. Although not coupled to G-proteins, C5aR2 has been shown in mouse models of sepsis to worsen mortality, linking C5a-C5aR2-mediated production of HMGB1 [9] . However, recent evidence indicates that C5aR2 signaling might play protective anti-inflammatory roles, as selective C5aR2 activation in human macrophages in vitro has inhibited cytokine secretion in response to a wide variety of immune cell activators [10] . Considering that C5aR2 robustly recruits and may signal through βarrestins [5] , this pathway should be carefully considered when targeting the C5a-C5aR1 axis to simultaneously engage both pathways and potentially yield more favorable outcomes. Another important caveat of the in vivo murine study performed by Carvelli and colleagues [1] is that avdoralimab was administered prophylactically in mice to reduce C5a-mediated lung injury, which might not correlate with an actual clinical setting, assuming that avdoralimab in theory, would be administered to already-infected individuals. Thus, the timing of putative anti-C5aR1 treatments would be an important consideration when treating COVID-19 individuals, ensuring that the blockade of C5aR1-signaling occurs at a time where there is active C5aR1-mediated recruitment of study performed by Carvelli and colleagues [1] , accumulation of C5aR1-expressing macrophages around the arteries and in the thrombus were observed in endoarteritis lesions. Whether blockade of complement C5aR1 signaling might also impact on endothelialitis-associated microthrombosis in COVID-19 disease, remains to be determined.

In conclusion, the study by the Vivier and Explore COVID-19 Marseille Immunopole groups [1] potentially opens the door for a new direction in COVID-19 research that focuses on targeting the 

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19: Complement, Coagulation, and Collateral Damage

Complement as a target in COVID-19?

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Emerging Insights into the Structure and Function of Complement C5a Receptors

Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Functional roles for C5a receptors in sepsis

C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications